Article Details
Retrieved on: 2024-08-13 22:18:40
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
New Jersey-based Merck will evaluate CN201 as a treatment for B-cell malignancies and investigate its potential for treating autoimmune diseases. “ ...
Article found on: www.bioprocessintl.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here